Hyderabad-based Bharat Biotech's vaccine, Covaxin, received the much-awaited Emergency Use Listing (EUL) from the World Health Organization (WHO) on Wednesday, bringing relief to students, business travelers, and all those who intend to travel abroad.
The WHO decided to grant the EUL after a risk-benefit assessment of Covaxin for global use. It said in a tweet: “WHO has granted emergency use listing (EUL) to Covaxin (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of Covid-19."
"This emergency use listing expands the availability of vaccines, the most effective medical tools we have to end the pandemic," said Dr Mariângela Simão, WHO's assistant director-general for Access to Medicines and Health Products.
This makes Covaxin the sixth vaccine to receive EUL after the Pfizer-BioNTech, AstraZeneca, Johnson & Johnson-Janssen, Moderna, and Sinopharm vaccines.
この記事は Business Standard の November 04, 2021 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、8,500 以上の雑誌や新聞にアクセスしてください。
すでに購読者です ? サインイン
この記事は Business Standard の November 04, 2021 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、8,500 以上の雑誌や新聞にアクセスしてください。
すでに購読者です? サインイン
Chennai In Wait-And-Watch Mode: Will CSK Paint The Town Yellow?
Come Saturday, hundreds and thousands of Chennai's 6.6 million people, and millions of fans outside the city, will be rooting for Chennai Super Kings (CSK) as they clash against Royal Challengers Bangalore (RCB).
Financial Markets Prefer Stability, Predictability: FM
Warns of unchecked explosion in F&O retail trades
I Never Do Hindu-Muslim Politics: Modi
Celebrated Eid; Oppn tarnished image among Muslims after 2002: PM
India's Al Spend May Touch $5 bn By 2027
Spending on artificial intelligence (AI) in India is expected to grow at a compound annual growth rate of 31.5 per cent from 2023 and might reach $5.1 billion by 2027, according to a joint study released on Tuesday by Intel and International Data Corporation (IDC).
Multiple launches to boost Cipla's margin prescription
The shares of pharma major Cipla slipped by about 4 per cent on Tuesday, after gaining over 5.6 per cent a day earlier.
Novelis files papers in US for IPO
Novelis, Hindalco Industries' US subsidiary, has filed a registration statement on Form F1 for its proposed initial public offering (IPO) with US securities regulator Securities and Exchange Commission (SEC), the firm said.
MF investment strategy: Be wary of rich valuations
Mutual fund investors are in the crosshairs due to the widespread offloading of stocks by foreign institutional investors (FIIs), expensive valuations of the Indian markets compared to global peers, and nervousness ahead of the Lok Sabha election results.
MFS EMBRACE HEALTHCARE, FINANCE STOCKS AS SMALLCAPS BOUNCE BACK
Mutual funds (MFS) embraced smallcap shares across sectors like healthcare, hospitality, and financial services, as the net inflows bounced back in April from the March lows.
JSPL stock factoring in improving prospects
THE COMPASS DEVANGSHU DATTA Jindal Steel & Power's (JSPL's) Q4FY24 results were in line with consensus.
Ease penal action for glitches, Mils appeal to Sebi
Regulator to seek suggestions applicability of financial disincentives